Purpose: To describe nongenetics clinicians' perceptions and knowledge of cancer genetics and laws prohibiting genetic discrimination, attitudes toward the use of cancer genetic testing, and referral practices. Methods:
Genetic cancer risk assessment (GCRA) is a process that includes genetic counseling and testing to assess an individual/ family's cancer risks, and to guide screening and prevention efforts. Cancer predisposition testing has become standard of care for numerous heritable cancer syndromes (e.g., hereditary breast/ovarian cancer, familial adenomatous polyposis, and multiple endocrine neoplasia). 1, 2 However, perceived potential for genetic discrimination (GD; "discrimination directed against an individual or family based solely on an apparent or perceived genetic variation from the 'normal' human genotype") is a barrier to GCRA. [3] [4] [5] [6] [7] [8] [9] Although GD can be subtle, such as social stigma, the major concern is health, life, or disability insurance and/or employment discrimination.
Legislation such as the Health Insurance Portability and Accountability Act (HIPAA) 10, 11 provides some protection in the group health insurance market, and 47 states have passed laws providing varying protection for health, life, and/or disability insurance. 12 All of the above applies exclusively to asymptomatic genetic traits (e.g., individuals with no personal history of cancer). California was among the earliest (some provisions enacted in 1992) to provide such coverage. In addition, Executive Order 13145, "to prohibit discrimination in federal employment based on genetic information," was signed into law on February 8, 2000 . Although in recent rulings the meaning of disability, unrelated to cancer genetics, may have diluted the level of protection, the Americans with Disabilities Act theoretically provides some employment protection for individuals with a genetic predisposition. 13 The Equal Employment Opportunity Commission action in the Burlington Northern case represented its first Americans with Disabilities Act lawsuit challenging an employer's administration of a genetic test in 2001. 14 Although some studies report instances of GD by health insurance companies, [15] [16] [17] their methodology included nonrepresentative sampling methods, admixture of cases with and without family history, affected and presymptomatic individuals, and cases with and without genetic testing. 7, 18 It is possible that more subtle forms of GD may exist, and the level of protection conferred by respective GD legislation is uncertain absent experience with violations, interpretation, and legal precedent. Nonetheless, to date, there is no case law documenting health insurance discrimination based on presymptomatic GCRA. Yet patients and health care providers perceive a high risk for potential GD despite federal and state protective legislation. 5,6,19 -22 There has been so little documented about actual discrimination, one does not necessarily know how "imperfect" the protections are or are not. This lack of understanding about the existing laws and general mistrust of insurance companies may contribute to an underlying sense of unease about genetic testing.
Clinicians' perceptions and lack of knowledge of cancer genetics and protective legislation may limit access to genetic testing and appropriate cancer risk screening and prevention. 19 Primary care clinicians are often gatekeepers for access to care, and oncology clinicians also influence GCRA referrals. 2 Knowledge of protective legislation for clinical cancer genetics and referral patterns has not been previously surveyed. The purpose of this study was to survey nongenetics clinicians (hereafter referred to as "clinicians"), to explore the extent to which knowledge gaps and perceptions about cancer genetics, GD, and protective laws influence cancer genetics referrals.
MATERIALS AND METHODS

Target population/sampling
Because state laws regarding GD vary across the country, we restricted eligibility to practicing clinicians in California, a state with relatively comprehensive statutes that have been established for more than 10 years. To enable a cross section of clinicians in California, we generated a sampling frame of (1) random stratified sampling of 1600 physicians from California Medical Association (CMA), including only those from primary care specialties of medical oncology, internal medicine, family medicine, and obstetrics/gynecology; and (2) the membership of nurse practitioners (NP) from the California Association of Nurse Practitioners (CANP). CMA is an advocacy organization that represents more than 30,000 California physicians. At the time of the survey CANP had 2092 members with contact information. To increase minority clinician representation and generalizability of results, the California Latino Medical Association (CaLMA) physician membership of 2524 was sampled, and the CMA database was over-sampled for members (n ϭ 1993) practicing in urban zip codes. Enriching for individuals in urban cores also enabled targeting areas where cancer genetics services are available, thus allowing greater opportunity to observe the relationship between knowledge and perceptions of GD and referral behavior.
Instruments
Survey description
The study employed a 47-item survey of perceptions, knowledge, and behavioral intent (referral patterns) regarding cancer genetics and GD, along with basic demographics (gender, age, race/ethnicity), practice setting, and patient populations. Ten Likert scale items investigated attitudes and beliefs toward cancer genetic testing and issues of GD: use and benefit of genetic testing (6); confidence in recognizing hereditary cancer patterns (1); insurance issues and GD concerns (3). Seventeen items assessed knowledge: knowledge of protective federal legislation (HIPAA) (4); California state protective legislation (5); cancer genetics knowledge (3); recognition of families appropriate for referral (5) . 23, 24 Respondents who indicated they had not referred patients for genetic counseling were instructed to select reasons for nonreferral from nine choice options. A separate section asked for open-ended description of why they were or were not comfortable referring patients. This section could be mailed separately if desired and contact information could be voluntarily included to facilitate clarification of responses. The survey took approximately 20 minutes to complete.
Survey validity
Survey items were based on a previously validated pilot study. 19 The survey underwent revisions by developers and experts from the Cancer Legal Resource Center at Loyola Law School and City of Hope's Cancer Genetics Education Program and Nursing Research and Education faculty. Items were classified into attitudes, behavioral intent, and knowledge categories, and rated and revised for clarity, importance in assessing beliefs, behavioral intent, knowledge, and relevance to GD.
Survey reliability
Interitem associations within attitude, behavior, and knowledge items were previously examined in a pilot survey (n ϭ 129) and results informed survey revision. 19 The coefficient alpha values for internal consistency reliability of survey scales derived from data obtained in this study were Genetic Testing Attitudes (three items) 0.65; Attitudes toward Genetic Testing (seven items) 0.78; Overall Knowledge of Cancer Genetics and Discrimination (17 items) 0.71; and Knowledge of Genetic Discrimination (nine items) 0.77.
Procedures
Two mechanisms encouraged survey response: (1) incentives of a $25 honorarium for physician (MD) respondents and a $5 coffee gift card for NP respondents; and (2) a modified version of Dillman response rate methodology. 25 
Survey administration
The survey was deployed as a scannable form, obtained by participant request via a prequalification postcard and returned by mail or fax, and as an online survey. As originally described, the Dillman method consists of a mailed questionnaire followed by a postcard 1 week later, a questionnaire on the third week and a final letter with questionnaire via certified mail after 7 weeks. 25 We modified the Dillman mailing methodology in two ways: (1) a prequalification postcard was substituted for the survey to minimize response bias based on survey content; and (2) postcard reminders were used for the second through fourth mailings, and a letter on the respective professional association letterhead was used for the final invitation. Because of an estimated overlap of 20 -25% with CMA, CaLMA members were asked to disregard the invitation if they had already completed the survey.
Data analysis
Data were audited for accuracy and respondents not in active practice were removed. Out of range values were corrected or set to missing. Attitude items were recoded so that high scores represented positive attitudes, and scales were tested for reliability. Knowledge items were scored as correct or incorrect, and knowledge scales were tested for reliability. Data were analyzed using SPSS for Windows, v 15.0 and descriptive statistics were calculated.
Knowledge and attitudes were compared by profession and by age group (under 50; 50ϩ) using independent t tests. Oneway analysis of variance was used to examine differences in attitudes and knowledge according to race/ethnicity, work settings, and specialty. Two forward stepwise logistic regression analyses controlling for demographic and practice characteristics in an initial block, were used to identify significant explanatory binary variables of (1) being comfortable referring patients for genetic counseling and (2) actually making referrals. The overall knowledge score was analyzed, and then replaced by the knowledge of GD law for the other analysis. We exclude (from reported referrals analyses) those respondents indicating that they had no opportunity to refer because they had not seen high risk patients, and those indicating that no genetic counseling services were available to them.
Qualitative data were organized by central topic, with overlapping themes placed in the predominant category. Because of the highly public nature of issues surrounding genetics and genetic information, a validity threat log was kept of news items, lay-press, or professional articles that could affect the beliefs, knowledge, and behavior of the population sampled. A review of 1997-1998 lay and professional articles indicated considerable coverage about the HIPAA enacted in 1996. California was one of the first states to enact protections and provided more protection than many other states. A search of professional and trade journals and the Los Angeles Times newspaper archives revealed minimal GD-related publicity during the study period. 
RESULTS
A total of 1222 clinicians responded to the survey; 98% were in active practice. Sixteen incomplete surveys and 25 responders no longer practicing were discarded, leaving 1181 valid surveys. The response rate and margin of error was 19.3 Ϯ 3.3% for CMA, and 20.3 Ϯ 4% for CANP, with 618 valid surveys for CMA and 447 for CANP. Supplemental sampling of CaLMA to increase minority accrual yielded 116 qualified responders. The degree of overlap between the CaLMA and CMA databases is uncertain-survey instructions for the CaLMA members told them to ignore the invitation if they had already responded via CMA. The majority of respondents were CMA members for whom some practice information was available. The intended specialty and practice-type distributions were achieved using proportional random sampling. Respondents were equivalent to CMA members sampled in specialty distribution, but were more likely to be in very large practices (37%) than were nonrespondents (30%). In addition, 91% of respondents practiced within an urban core (based on zip code). Respondents' demographic and practice setting data are displayed in Table 1 . Table 2 displays responses to cancer genetic testing and insurance discrimination items. The 4-point scale represented in Table 2 represents the answer choices of "strongly agree" (4), "agree," "disagree," and "strongly disagree" (1). Overall, respondents had a positive attitude toward the benefits of genetic testing (3.1 on a 4-point scale, SD ϭ 0.42; data not shown) but they tended to perceive that GD exists on questions regarding genetic testing and insurance (mean score 2.3 on a 4-point scale, SD ϭ 0.57; data not shown). Three-quarters thought that patients might decline testing because of fear of health insurance discrimination. Slightly more than half thought that testing created health insurance problems for their patients with and without cancer.
Attitudes/beliefs toward hereditary cancer genetic testing and GD issues
Knowledge of cancer genetics and GD law
Cancer genetics and GD law knowledge outcomes are summarized in Table 3 . Half of the respondents knew the correct answer to at least two of the three questions regarding cancer risks for a woman with a BRCA gene mutation. When given five hypothetical family cancer histories, only 30% correctly identified four or more scenarios as appropriate or inappropriate for genetics referral.
Fewer than 24% of federal and 34% of state law questions were answered correctly.
The mean overall knowledge score (combined knowledge of discrimination laws and cancer genetics) was 41% (Fig. 1) . MDs had greater knowledge, on both overall survey questions and on questions specific to GD, than NPs (P Ͻ 0.001). There were no significant differences in knowledge by race/ethnicity, work setting, or practice specialty, but overall knowledge was significantly greater for respondents in the urban versus rural core (P ϭ 0.012). Age data did not show meaningful differences in knowledge (Ͻ50 ϭ 2.40, 50ϩ ϭ 2.71) or attitudes (Ͻ50 ϭ 3.09, 50ϩ ϭ 3.17). Few respondents achieved Ն80% correct in the knowledge questions (MDs: 3.8% [24/722] ; NPs: 1.4% [6/436] ). Of the 30 who scored Ͼ80% on the knowledge questions the majority were MD (24), white (20) , age 50ϩ, practicing in the clinic Ͼ90% of the time (18) , in an urban core (27) .
Behavioral intent/practice
About two-thirds of respondents (63.3%) indicated that they were comfortable recommending genetic counseling to patients potentially at high risk for cancer, but only 45% (532) had done so. The predominant theme among 722 comments describing why respondents were comfortable recommending genetic counseling was the demonstrated clinical use of testing, as evidenced by the following response: "It will identify who needs invasive screening or prophylactic treatment." Among the referrers, 37% stated they have suggested patients pay out of pocket for genetic testing. Of these, 48% indicated that concern about GD was a reason for suggesting patients pay out of pocket. The two main referral barriers were lack of opportunity and an unclear referral process (Fig. 2) .
Frequent themes from 424 comments describing why respondents were not comfortable recommending genetic counseling was regarding the lack of medical evidence to support testing and the lack of referral guidelines. For example:
• "Not sure if it is reliable, how to advise patients on results;"
Some clinicians reported that they lacked the necessary knowledge base to appropriately identify or advise patients:
• "Don't have the training to know what to order and what the results mean;" • "I need to do more review, based on questions above." Of the 55% who did not refer, 0.7% did not refer because they perform genetic counseling/testing for their patients themselves.
Stepwise logistic regression analyses identified a positive attitude toward genetic testing as the strongest predictor of referral (Table 4) . For each one point increase in attitude, the likelihood of referral increased 3.5 times (odds ratio: 3.55 [95% confidence interval: 2.24 -5.63], P Ͻ 0.001). The higher the belief in GD, the less likely a participant was to refer, whereas more knowledge of GD law was associated with both comfort recommending and actual referral. The higher the percent of underserved patients a respondent had, the less likely they were to refer their patients for genetic counseling and testing.
DISCUSSION
Genetic testing for predisposition to common cancers, such as breast and colorectal cancer, has been available clinically for more than 10 years. This testing is increasingly supported by evidence-based documentation on the efficacy of screening and risk reduction interventions. 26 -29 As such, GCRA is considered standard of care for numerous heritable cancer syndromes. 2, 24 Nonetheless, potential barriers to participation include high cost of genetic tests and inconsistent insurance coverage, limited lay and professional knowledge about clinical cancer genetics referral guidelines, and fears about potential GD among patients 6,30 -32 and clinicians. 19, 20, 22, 33 Results of a phone survey at Washington State indicated that 60% of 1450 adults were concerned about GD. 21 In a survey of 163 cancer genetic specialists choices for care if they were at 50% risk of carrying a hereditary predisposition to cancer, 68% stated they would not bill their insurance company because of concerns about GD. 22 Although a recent follow-up survey of cancer genetic counselors indicated less concern about GD and more willingness to use health insurance for genetic testing, 34 we found that nongenetics clinicians still harbor significant GD concerns and that these concerns influence referral practice. 
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To our knowledge, this is the first comprehensive survey of knowledge and perceptions about GD and protective legislation among primary care and specialty clinicians who directly influence access to GCRA. Despite an overall favorable view of the potential benefits genetic testing may have on medical management for patients and family members, there were concerns about possible GD and inadequate knowledge about laws prohibiting the use of genetic information to determine health insurance eligibility. Clinicians also perceived that their patients were concerned about the potential for GD. Nedelcu et al. 19 observed similar levels of GD concern in 271 clinicians before their attendance at cancer genetic seminars, with 52% believing that mutation carriers have difficulty obtaining health insurance. Concerns about GD were also reported by Freedman et al., 20 who surveyed 1251 US physicians from 1999 to 2000, and a 1997 survey of Alabama primary care physicians revealed concerns that genetic testing could lead to employment and insurance discrimination. 35 However, specific knowledge of protective legislation was not surveyed in the latter two studies.
Although clinicians in our study had greater knowledge of federal law (HIPAA) than California laws, the overall level of knowledge of GD protective legislation and of cancer genetics principles was low. We believe that the respondents are adequately representative of the clinicians sampled, because we minimized responder bias by using a prequalification postcard that described the survey topic as cancer genetics with no allusion to GD, and the specialty and practice-type distributions of respondents and nonrespondents were comparable. However, low response rates to physician surveys has been a concern, 36 -38 and is echoed here, tracking recent trends toward reduced time per patient and increased paperwork.
Over sampling individuals in urban cores where cancer genetics services are often located allowed greater opportunity to observe whether knowledge and perceptions of GD influence referral behavior. Respondents with a higher percentage of underserved patients had lower referral rates. This likely reflects a disparity in access to care, in that public health coverage for indigent patients (e.g., Medicaid) does not usually provide coverage for genetic testing. We and others have demonstrated that underserved populations are willing to participate in GCRA and/or cancer screening and prevention activities absent the systemic barrier. 39 -41 It is unclear how effective existing and emerging federal and state legislation will prove to be. Nonetheless, to date there are few documented incidents of health insurance discrimination in the cancer genetics setting. HIPAA prohibits insurers from charging different individual premiums within a group plan Table 4 Logistic regression of (1) and states that genetic information cannot be used to determine eligibility, and that genetic information cannot be viewed as a pre-existing condition (". . . in the absence of a diagnosis of the condition related to such information"). However, HIPAA does not prohibit access by insurers to genetic information, prohibit the insurer from demanding genetic testing as a condition of coverage, protect against group rate hikes or provide protection outside the group market (individual policies are not covered).
Since 1991, at least 47 states have enacted some form of legislation addressing genetic issues. 42 Protective legislation in California, some of the most comprehensive in the nation, may not be representative of law in many other states. Consequently, our results may not be entirely generalized for other states. The knowledge deficits and perceptions we observed may be greater in states with more recently enacted or less well-publicized laws. It is important to recognize as well that the legislated protections apply exclusively to individuals with asymptomatic genetic traits. The problem of potential adverse action by insurers because of new symptomatic disease is common to health care coverage in general. It would be very challenging to discern any incremental effect of the genetic information superimposed on the primary issue of a symptomatic cancer.
Although the majority of clinicians in our study indicated that they were comfortable referring patients for genetic counseling, less than half had referred and few had provided genetic testing for their patients themselves. Wideroff et al. 43 also reported that most clinicians referred patients rather than ordering genetic tests themselves.
The majority of clinicians in this study believed they could recognize hereditary cancer patterns, but more than twothirds were not able to identify appropriate cases for referral. This raises concerns about the quality of referrals and possible under-recognition of patients appropriate for GCRA. Previous studies highlighted important gaps in physician/nurse knowledge regarding genetic testing and cancer genetics. 20, 44, 45 Moreover, a survey of patients revealed that they often perceive their primary care providers as having limited knowledge regarding genetics, which may discourage patients from discussing genetic testing with them. 46 Although not addressed in this study, there are also significant concerns about privacy of genetic information. Few state laws, outside California and Minnesota, prohibit disclosure of genetic information; even there, following the provisions is difficult in actual practice. These issues highlight the need for comprehensive legislation prohibiting the misuse of that information.
Overall, our results and the extant literature indicate that knowledge gaps and perceptions are barriers to GCRA referrals. Clinicians were concerned about the potential for GD and were ill-informed about existing federal and California state protective laws. The comments demonstrate a need for and interest in more educational opportunities in this area. More comprehensive federal law, increased education for clinicians about the use of GCRA, referral guidelines, and legal protections against GD should enhance access to risk-appropriate cancer screening and prevention. 47, 48 The GINA (Genetic Information Nondiscrimination Act) of 2008 was recently approved by the House of Representatives by a vote of 414 to 1 and passed unanimously by the Senate. President Bush signed GINA into law on May 21, 2008, with most provisions taking effect in 6 -12 months. GINA generally stipulates the following:
1. GINA prohibits employers from requesting, requiring, or purchasing genetic information; requiring an individual to take a genetic test as a condition of employment; or discriminating on the basis of "genetic information." This term is defined as "information about an individual's genetic tests, the genetic tests of family members, or the occurrence of a disease in family members of the individual." 2. GINA does not apply to individuals who have a "manifestation of a disease, disorder, or pathologic condition." These terms are not defined. 3. GINA prohibits health insurance companies from denying or canceling coverage based on genetic information. However, GINA does not apply to life insurance, disability insurance, or long-term care insurance. However, because GINA does not provide comprehensive protection outside the health insurance market against GD, it remains unclear whether GINA will affect the willingness of at-risk individuals to undergo genetic testing.
However, this new law provides a federal framework for protections based on a genetic predisposition for a disease, instead of the patchwork of state laws throughout the country. Congress found that "while many states have enacted some type of genetic nondiscrimination law, these laws vary widely with respect to their approach, application, and level of protection. Congress has collected substantial evidence that the American public and the medical community find the existing patchwork of State and Federal laws to be confusing and inadequate to protect them from discrimination." The uncertainty of how test results might be used has led many to refuse testing because of fear of employers using the genetic test results against them or of insurance companies denying coverage.
And, as GINA further states, "[g]enetic testing can allow individuals to take steps to reduce the likelihood that they will contract a particular disorder. New knowledge about genetics may allow for the development of better therapies that are more effective against disease or have fewer side effects than current treatments."
The mapping of the human genome shows great promise for making medical care more preventive and effective and for new treatments to be developed. GINA, by providing protection in both the group and individual health insurance markets and in the employment arena, shows great promise to provide the protections that the people need to have confidence going forward. Nonetheless, it will remain to be seen how much protection GINA provides once it goes into effect. As highlighted in this study, we believe education for clinicians on both exist-ing and new legislation and on cancer genetics practice guidelines will result in more confident and appropriate usage of GCRA and testing, which will lead to risk-appropriate cancer screening and prevention measures in high-risk individuals.
